Premium
F‐18 FDG PET / CT quantization parameters as predictors of outcome in patients with diffuse large B ‐cell lymphoma
Author(s) -
Gallicchio Rosj,
Mansueto Giovanna,
Simeon Vittorio,
Nardelli Anna,
Guariglia Roberto,
Capacchione Daniela,
Soscia Ernesto,
Pedicini Piernicola,
Gattozzi Domenico,
Musto Pellegrino,
Storto Giovanni
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12268
Subject(s) - nuclear medicine , medicine , diffuse large b cell lymphoma , univariate analysis , standardized uptake value , lactate dehydrogenase , positron emission tomography , lymphoma , chemotherapy , multivariate analysis , physics , nuclear magnetic resonance , enzyme
Abstract Aim We evaluated the prognostic significance of standardized uptake value ( SUV max), metabolic tumor volume ( MTV ), and total lesion glycolysis ( TLG ) obtained by F ‐18 FDG PET / CT ( PET / CT ) in patients with diffuse large B ‐cell L ymphomas ( DLBCL ) presenting intermediate IPI score. Material and Methods Fifty‐two patients (61 ± 13 yr) underwent PET / CT before the first‐line chemotherapy. The mean SUV max value, the summed MTV (cm 3 ; 42% threshold), and the cumulative TLG (g) were registered. The patients were followed up 18 months thereafter (range 3–41 months). The PET / CT results were compared to the event‐free survival ( EFS ). Results At univariate analysis, SUV max and lactate dehydrogenase ( LDH ) levels were predictive, but discordantly. The K aplan– M eier survival analysis for SUV max showed a significant better EFS in patients presenting higher values as compared to those having lesser ( P = 0.0002, HR 0.13). Summed MTV and cumulative TLG were not suitable for predicting EFS . Conclusion Despite the availability of new tools for the quantitative assessment of disease activity on PET / CT , the SUV max rather than MTV and TLG remains the only predictor for EFS in DLBCL patients. The magnitude of glycolytic activity rather than the amount of metabolically active burden holds a predominant value for determining the response to chemotherapy in DLBCL .